EPO and post-traumatic stress disorder: This review summarizes the recent developments and highlights novel pharmacological targets for PTSD and CVD, including lactylation of histone and non-histone proteins, along with the related biomolecular actors, HIF-1α, EPO, ASC1 channels, CD147, and IL-7 (Figure 1).